Why the study?
Does pre-treatment with anti-idiotypic antibodies reduce inflammatory myocarditis in CVB3-challenged mice?
Does pre-treatment with anti-idiotypic antibodies reduce inflammatory myocarditis in CVB3-challenged mice?
Anti-idiotypic antibodies can modulate the immune response and reduce inflammatory myocarditis in a murine model of Coxsackievirus B3 infection.
Hypothesis-generating in murine CVB3 myocarditis; leaves open translation to human viral heart disease.
Pre-treatment of syngeneic mice with polyclonal populations of Protein-A separated anti-idiotypic antibodies prepared against anti-CVB3 viral idiotypes resulted in reduction of inflammatory myocarditis in virus-challenged mice. Cellular immunity as assessed by cell-migration-inhibition resulted in specific cell-mediated sensitivity against anti-Ids (CVB3) as well as viral preparations. Animals pre-treated with anti-idiotypic preparations developed an anamnestic anti-viral antibody response, with antibodies capable of specifically binding CVB3 virus antigen in an ELISA assay; but without CVB3 viral neutralizing capability. Adoptive transfer of limited numbers of syngeneic anti-Id immunized lymphoid cell populations failed to alter the course of inflammatory myocarditis in CVB3 virus-challenged animals. Cellular binding studies utilizing anti-Ids suggested increased, but nonspecific binding of anti-Ids to lymphoid and myocyte populations in CVB3 infected animals. The data suggest an immunomodulatory role of idiotype-anti-idiotype interactions in the development of myocarditis.
No takes yet. Share an insight, caveat, or question.
Paque et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: